POLE mutation
|
Solid Tumor
|
POLE mutation
|
Solid Tumor
|
Immunotherapy Sensitive: B - Late Trials
|
Immunotherapy Sensitive: B - Late Trials
|
POLE mutation
|
Endometrial Cancer
|
POLE mutation
|
Endometrial Cancer
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
POLE mutation
|
Gastric Cancer
|
POLE mutation
|
Gastric Cancer
|
CP-675206 Sensitive: C2 – Inclusion Criteria
|
CP-675206 Sensitive: C2 – Inclusion Criteria
|
POLE mutation
|
Gastric Cancer
|
POLE mutation
|
Gastric Cancer
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
POLE mutation
|
Solid Tumor
|
POLE mutation
|
Solid Tumor
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|
POLE mutation
|
Endometrial Cancer
|
POLE mutation
|
Endometrial Cancer
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|
POLE mutation
|
Solid Tumor
|
POLE mutation
|
Solid Tumor
|
toripalimab Sensitive: C2 – Inclusion Criteria
|
toripalimab Sensitive: C2 – Inclusion Criteria
|
POLE mutation
|
CRC
|
POLE mutation
|
CRC
|
nivolumab Sensitive: C2 – Inclusion Criteria
|
nivolumab Sensitive: C2 – Inclusion Criteria
|
POLE mutation
|
Solid Tumor
|
POLE mutation
|
Solid Tumor
|
dostarlimab Sensitive: C2 – Inclusion Criteria
|
dostarlimab Sensitive: C2 – Inclusion Criteria
|
POLE mutation
|
Melanoma
|
POLE mutation
|
Melanoma
|
PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials
|
POLE mutation
|
Cholangiocarcinoma
|
POLE mutation
|
Cholangiocarcinoma
|
PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials
|
POLE mutation
|
NSCLC
|
POLE mutation
|
NSCLC
|
PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials
|
POLE mutation
|
CRC
|
POLE mutation
|
CRC
|
PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor + PD-L1 inhibitor Sensitive: C3 – Early Trials
|
POLE mutation
|
Melanoma
|
POLE mutation
|
Melanoma
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
POLE mutation
|
Cholangiocarcinoma
|
POLE mutation
|
Cholangiocarcinoma
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
POLE mutation
|
NSCLC
|
POLE mutation
|
NSCLC
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
POLE mutation
|
CRC
|
POLE mutation
|
CRC
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
POLE mutation
|
Melanoma
|
POLE mutation
|
Melanoma
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
POLE mutation
|
Cholangiocarcinoma
|
POLE mutation
|
Cholangiocarcinoma
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
POLE mutation
|
NSCLC
|
POLE mutation
|
NSCLC
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
POLE mutation
|
CRC
|
POLE mutation
|
CRC
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
POLE mutation
|
CRC
|
POLE mutation
|
CRC
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
POLE mutation
|
Gastroesophageal Cancer
|
POLE mutation
|
Gastroesophageal Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
POLE mutation
|
NSCLC
|
POLE mutation
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
POLE mutation
|
Endometrial Cancer
|
POLE mutation
|
Endometrial Cancer
|
nivolumab Sensitive: C4 – Case Studies
|
nivolumab Sensitive: C4 – Case Studies
|